13 Jul 2023 , 01:53 PM
The US health agency has given the generic Sevelamer hydrochloride tablets used to regulate serum phosphorus in patients with chronic kidney disease (CKD) receiving dialysis its final approval, according to Aurobindo Pharma Ltd.
According to Aurobindo Pharma’s regulatory filing, the US Food & Drug Administration (USFDA) has approved the manufacture and marketing of Sevelamer hydrochloride tablets in strengths of 400 mg and 800 mg.
The 400 mg and 800 mg Renagel pills from Genzyme Corporation are bioequivalent and medically equivalent to these tablets, according to the statement.
According to the business, which cited IQVIA statistics, the approved product’s market size is anticipated to be roughly USD 37 million for the 12 months ending in May 2023.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
